- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02461602
Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients (ELITE)
Eliminate Thromboembolism (ELITE): Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
ELITE will be a prospective, multicenter observational study of 500 participants to characterize demographics, comorbidities, risk profiles, socioeconomic status, and patient preferences related to anticoagulation management. The primary study endpoint will be warfarin discontinuation without resumption as documented in the medical record. Secondary outcomes of interest include warfarin adherence and factors associated with suboptimal adherence and/or permanent discontinuation. Clinical data, including demographics, medical history, and comorbidities, will be abstracted and entered by site coordinators. An internal survey developed by Duke Clinical Research Institute (DCRI) will be administered to patients during regularly scheduled clinic visits. Survey items will include patient treatment priorities, perceived risk of bleeding and/or stroke, barriers to adherence, and treatment satisfaction. Subjects will complete a survey at baseline and at the followup visit closest to 6 months after enrollment.
This study will provide the foundation for numerous potential future questions about medication adherence and barriers to treatment, such as a survey on physician preferences/ shared decision-making (concordance between physician and patient preferences), followup to capture clinical events, and interventions to improve long-term medication adherence in AF.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
California
-
Pasadena, California, Forenede Stater, 91105
- Foothill Cardiology
-
-
Florida
-
Coral Springs, Florida, Forenede Stater, 33065
- Holy Cross Medical Group
-
Port Charlotte, Florida, Forenede Stater, 33952
- Charlotte Heart Group
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30350
- Atlanta Institute for Medical Research, Inc.
-
Cumming, Georgia, Forenede Stater, 30041
- Atlanta Heart Specialists
-
-
Indiana
-
Munster, Indiana, Forenede Stater, 46321
- Cardiovascular Research of Northwest Indiana, L.L.C.
-
-
Kentucky
-
Owensboro, Kentucky, Forenede Stater, 42303
- Research Integrity, LLC.
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70121
- Ochsner Health System
-
-
Maine
-
Rockport, Maine, Forenede Stater, 04856
- Penobscot Bay Medical Center
-
-
Michigan
-
Alpena, Michigan, Forenede Stater, 49707
- Endeavor Medical Research
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Great Lakes Heart and Vascular Institute
-
-
Minnesota
-
Saint Paul, Minnesota, Forenede Stater, 55102
- HealthEast Medical Research Institute
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- Jackson Heart Clinic
-
-
New Jersey
-
Elmer, New Jersey, Forenede Stater, 08318
- Cardiovascular Associates of the Delaware Valley
-
Voorhees, New Jersey, Forenede Stater, 08043
- Lourdes Cardiology Services
-
-
North Carolina
-
Lumberton, North Carolina, Forenede Stater, 28358
- Duke Cardiology of Lumberton
-
-
Pennsylvania
-
Doylestown, Pennsylvania, Forenede Stater, 18901
- Doylestown Health Cardiology
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29203
- Columbia Heart Clinic, PA
-
-
Texas
-
Allen, Texas, Forenede Stater, 75013
- North Texas Research Associates
-
Waco, Texas, Forenede Stater, 76712
- Providence Health Center
-
-
Virginia
-
Newport News, Virginia, Forenede Stater, 23601
- Riverside Cardiology Specialists
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- 18 years or older at the time of enrollment
- Electrocardiographically confirmed AF
- Able to complete patient-reported outcomes surveys
- Initiated warfarin therapy in the prior 3 months
- Ability to adhere to regular clinical visits
- Ability to sign informed consent
- Ability to read/comprehend/speak English
Exclusion Criteria:
- Anticipated life expectancy less than six months (as determined by the site investigator)
- Transient AF secondary to a reversible condition (hyperthyroidism, pulmonary embolism, post-cardiothoracic surgery)
- Recent Deep Venous Thrombosis(DVT) or Pulmonary Embolism (PE) (within 6 months)
- Participation in a randomized trial of anticoagulation for AF
- Use of a home international normalized ratio (INR) monitoring system
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Reason(s) for Warfarin discontinuation
Tidsramme: 6 months
|
6 months
|
Change in Warfarin adherence
Tidsramme: Baseline and 6 months
|
Baseline and 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Frequency of hospitalizations
Tidsramme: Baseline and 6 months
|
Baseline and 6 months
|
Frequency of bleeding events
Tidsramme: Baseline and 6 months
|
Baseline and 6 months
|
Change in INR values
Tidsramme: Baseline and 6 months
|
Baseline and 6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Emily O'Brien, PhD, DCRI
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Pro00061054
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Atrieflimren
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Pusan National University HospitalIkke rekrutterer endnuHjerteimplanterbar elektronisk enhed | Atrial High Rate EpisodeKorea, Republikken
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Henry Ford Health SystemTrukket tilbage
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Tilmelding efter invitationKortkoblet idiopatisk ventrikulær fibrillationHolland
-
Assiut UniversityTrukket tilbageASD2 (Secundum atrial septal defekt)
-
Nobles Medical Technologies II IncTilmelding efter invitationForamen Ovale, Patent | Septal defekt, atrial | Septaldefekt, HjerteForenede Stater, Italien
-
HeartStitch.ComUkendtForamen Ovale, Patent | Septal defekt, atrial | Septaldefekt, HjerteForenede Stater
-
Occlutech International ABAfsluttetSecundum atrial septal defekter
-
Institute of Cardiology, Warsaw, PolandUkendtOstium Secundum AtrieseptumdefektPolen